Member Info for Laura2022

Good to see Ant

Yes I took some in open offer and on market last week and have done well in GDR so intend to buy more down here

To buy

Contact the name.on the RNS maybe ?

Had 10%

Wait for large trades

Slater already out

Patience ; )

Agree waste...as I said yesterday they only have about 25%

As an aside CGH also trying same

A share called MEN did 400% in same horrible situation as the directors kept buying shares on open market to ensure the vote so maybe worth bearing in mind

Andersson and Labro Investments Ltd 333,053,462 45.75%

China Nonferrous Metals Int’l Mining Co. Ltd 22,469,289 3.09%

Directors (excluding Martin Andersson) 2,464,702 0.34%

Employee Benefit Trust 1,070,295 0.15%

Total Number of Shares in Issue: 728,056,182

Percentage of shares not in public hands: 46.68%

Really sorry to see this

With 50% acceptance will the holders buy more of CGH now it's just £2mln value

And another 1mln at 0 .7

Ageee

Based on the recent and continued strong performance of Playstack, which is trading ahead of expectations, the Board of TruFin confirms that the Group as a whole is trading in line with market expectations and remains on track to achieve EBITDA profitability in 2024. The Group also remains fully funded to profitability.

Agree

My purchases at 2.6p are well in profit

As well as the 90% on GDR this week

PYC (small fully funded bio tech well worth a look)

Large buys

Moving

GDR done 100% s8nce their placing

CPX 500%

Last year PYC did 200-300% after a quiet week or so after the July placing 2023

Hopefully more to come here...£1.2mln cap with c£600k cash and record booked revenues of £960k last year with £500k already booked in first 2 weeks of 2024/25

Can't buy much today

You are a complete snake sushi

You push this then go quiet or de ramp when it suits your agenda

Moving Forwards

The focus of the Company’s personalised dosing initiatives going forwards will be to expand the capability of the software to support dosing decision making around not only chemotherapeutic agents but GCSF. Both the ongoing PREDICT-ONC study and potential secondary research with DoseMe clients in the US will support this objective. In parallel, the Company is seeking ways to make the blood sampling required by its software more convenient for patients. This can potentially be achieved by using the software in other settings where frequent blood sampling already occurs, but also through exploration of the use of new diagnostic devices that can obtain and analyse blood samples in community or home settings (such at that being developed by our partner company Beyond Blood Diagnostics).

As the Company continues to develop its personalised dosing software, it will actively consider the most appropriate way to ring fence resources for this part of its business. Options under consideration include creation of a dedicated business unit, creation of a wholly owned subsidiary or a joint venture with a party with complementary technology/ capabilities. As further progress is made towards one of these, further updates will be provided accordingly.

As you well know a company like DEST is completely different as it's a drug DEVELOPER that has been burning £5-10mln per annum and needs £25mln and has gone from 150p to 3p in 12mths

But I guess you knew that

Ironically PYC actually helps these cash guzzlers SAVE money

Nice try

Strange that you NEVER post positively on ANY share amd actually hold ZERO investments anywhere seemingly

PYC also have a breakthrough product just like GDR

Any reason you've done a complete full circle in the last few.months Acker ?